Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders

被引:6
|
作者
Vassilopoulou, Emilia [1 ]
Efthymiou, Dimitris [2 ]
Papatriantafyllou, Evangelia [1 ]
Markopoulou, Maria [3 ]
Sakellariou, Efthymia-Maria [4 ]
Popescu, Alina Codruta [5 ]
机构
[1] Int Hellen Univ, Dept Nutr Sci & Dietet, Thessaloniki 57400, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Div Neurosci, Dept Psychiat, Thessaloniki 54124, Greece
[3] Psychiat Hosp Thessaloniki, Dept Forens Psychiat, Thessaloniki 56429, Greece
[4] Gen Univ Hosp, Psychiat Clin, Larisa 41110, Greece
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Abil Human Sci, Cluj Napoca 400012, Romania
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期
关键词
forensic psychiatry; antipsychotic drugs; metabolic disturbances; WEIGHT-GAIN; CARDIOMETABOLIC RISK; 1ST-EPISODE SCHIZOPHRENIA; DRUGS; ANTIDEPRESSANTS; ZIPRASIDONE; OLANZAPINE; QUETIAPINE; CLOZAPINE; LEPTIN;
D O I
10.3390/jpm11111189
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic (SGA) medication and experience metabolic and inflammatory side effects. Aim: In this paper, we monitored the three-year fluctuation of selected anthropometric, biochemical, and inflammatory indices in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of AP. Methods: Thirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain (WG) and metabolic complications. Biochemical, hematological, anthropometric, blood pressure (BP), and medication data were retrieved from the individual medical files. Statistical analysis was performed with SPSS 23. Results: No significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus (DM), lipidemia, and cardiovascular disease (CVD). In those taking AP1, the mean HDL level decreased significantly over time (p < 0.05) and a higher proportion developed higher BP (52.9% of AP1 vs. 16.7% AP2). In the AP2 group the median level of C-reactive protein (CRP) (p < 0.001) and the white blood cell count (WBC) increased over the three years (p < 0.001). Conclusions: The proposed sub-classification of SGAs into AP1 and AP2, depending on their potential for metabolic and inflammatory effects, might facilitate study of their long-term side-effects but also help in personalized prevention or treatment measures to counteract these side-effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] The Effects of Use of Long-Term Second-Generation Antipsychotics on Liver and Kidney Function: A Prospective Study
    Papatriantafyllou, Evangelia
    Efthymiou, Dimitris
    Markopoulou, Maria
    Sakellariou, Efthymia-Maria
    Vassilopoulou, Emilia
    DISEASES, 2022, 10 (03)
  • [2] Second-generation antipsychotics and the metabolic syndrome
    Prakash S. Masand
    Rajnish Mago
    Current Psychiatry Reports, 2005, 7 (3) : 153 - 154
  • [3] Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
    Mortimer, Katherine R. H.
    Katshu, Mohammed Zia Ul Haq
    Chakrabarti, Lisa
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [4] Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children
    Devlin, Angela M.
    Panagiotopoulos, Constadina
    PHARMACOGENOMICS, 2015, 16 (09) : 981 - 996
  • [5] Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
    Hirsch, Lauren
    Yang, Jaeun
    Bresee, Lauren
    Jette, Nathalie
    Patten, Scott
    Pringsheim, Tamara
    DRUG SAFETY, 2017, 40 (09) : 771 - 781
  • [6] The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
    Alrob, Osama Abo
    Alazzam, Sayer
    Alzoubi, Karem
    Nusair, Mohammad B.
    Amawi, Haneen
    Karasneh, Reema
    Rababa'h, Abeer
    Nammas, Mohammad
    MEDICINA-LITHUANIA, 2019, 55 (07):
  • [7] Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics
    Dhamane, Amol D.
    Martin, Bradley C.
    Brixner, Diana I.
    Hudson, Teresa J.
    Said, Qayyim
    JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (05) : 360 - 374
  • [8] Second-Generation (Atypical) Antipsychotics and Metabolic EffectsA Comprehensive Literature Review
    John W. Newcomer
    CNS Drugs, 2005, 19 (Suppl 1) : 1 - 93
  • [9] Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
    Jeong, Seong Hoon
    Lee, Nam Young
    Kim, Se Hyun
    Chung, In Won
    Youn, Tak
    Kang, Ung Gu
    Ahn, Yong Min
    You, Han Young
    Kim, Yong Sik
    PSYCHIATRY INVESTIGATION, 2018, 15 (06) : 628 - 637
  • [10] Sex differences in side effects of second-generation antipsychotics
    Christina Leotsakou
    Andreas Sardis
    Perikles Paterakis
    Annals of General Psychiatry, 7 (Suppl 1)